Lake Street Capital Begins Coverage on Plus Therapeutics (NASDAQ:PSTV)

Research analysts at Lake Street Capital started coverage on shares of Plus Therapeutics (NASDAQ:PSTV) in a research report issued on Tuesday. The brokerage set a “buy” rating and a $2.00 price target on the stock.

A number of other equities research analysts also recently weighed in on PSTV. Zacks Research downgraded Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $1.00 target price (down previously from $2.00) on shares of Plus Therapeutics in a research report on Friday, January 23rd. D. Boral Capital reduced their price target on shares of Plus Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, January 22nd. Finally, Ascendiant Capital Markets decreased their price target on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, November 21st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $5.80.

Plus Therapeutics Trading Up 6.1%

PSTV stock opened at $0.24 on Tuesday. The firm has a market cap of $33.61 million, a PE ratio of -0.13 and a beta of 0.89. The stock has a 50-day moving average price of $0.50 and a 200-day moving average price of $0.54. Plus Therapeutics has a 1-year low of $0.16 and a 1-year high of $2.31.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Scientech Research LLC bought a new stake in shares of Plus Therapeutics during the third quarter worth about $100,000. Susquehanna International Group LLP bought a new position in Plus Therapeutics in the 3rd quarter valued at about $46,000. Jane Street Group LLC acquired a new position in Plus Therapeutics during the 2nd quarter valued at about $41,000. Finally, Altium Capital Management LLC acquired a new position in Plus Therapeutics during the 3rd quarter valued at about $628,000. 3.28% of the stock is owned by institutional investors.

About Plus Therapeutics

Plus Therapeutics is a clinical?stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.